{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:20:41Z","timestamp":1770510041554,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.clinthera.2011.08.011","type":"journal-article","created":{"date-parts":[[2011,9,18]],"date-time":"2011-09-18T07:50:12Z","timestamp":1316332212000},"page":"1475-1482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes and Costs Associated With a History of Vancomycin Exposure in Patients With MRSA-Related Complicated Bacteremia and Infective Endocarditis"],"prefix":"10.1016","volume":"33","author":[{"given":"Jack","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.08.011_bib1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(06)68853-3","article-title":"Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat","volume":"368","author":"Grundmann","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.08.011_bib2","series-title":"Million Lives Campaign","year":"2007"},{"key":"10.1016\/j.clinthera.2011.08.011_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjmed.2006.01.004","article-title":"Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus","volume":"119","author":"Crum","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2011.08.011_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.08.011_bib5","series-title":"Performance Standards for Antimicrobial Disc Susceptibility Tests","year":"2010"},{"key":"10.1016\/j.clinthera.2011.08.011_bib6","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkn329","article-title":"Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"62","author":"Lodise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2011.08.011_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/dkm445","article-title":"Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"61","author":"Moise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2011.08.011_bib8","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/421092","article-title":"Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy","volume":"38","author":"Moise-Broder","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.011_bib9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1128\/AAC.46.5.1492-1502.2002","article-title":"Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin","volume":"46","author":"Sakoulas","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.08.011_bib10","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.011_bib11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1164\/ajrccm.163.7.9912080","article-title":"Outcomes of primary and catheter-related bacteremia","volume":"163","author":"Renaud","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2011.08.011_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.011_bib13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1378\/chest.122.4.1271","article-title":"Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia","volume":"122","author":"Paladino","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2011.08.011_bib14","series-title":"The Red Book","year":"2009"},{"key":"10.1016\/j.clinthera.2011.08.011_bib15","first-page":"800","article-title":"Microcost analysis of inpatient dispensing and administration of oral solids","volume":"47","author":"Hatoum","year":"1990","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2011.08.011_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10096-006-0096-0","article-title":"Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia","volume":"25","author":"Khatib","year":"2006","journal-title":"Eur J Clin Microbio Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.011_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/AAC.32.6.848","article-title":"Vancomycin pharmacokinetics in patients with various degrees of renal function","volume":"32","author":"Rodvold","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.011_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/AAC.22.3.391","article-title":"Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations","volume":"22","author":"Rotschafer","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.011_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/AAC.34.6.1165","article-title":"Application of a Bayesian method to monitor and adjust vancomycin dosage regimens","volume":"34","author":"Hurst","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.011_bib20","series-title":"Abstract presented at: 110th Meeting of the American Society for Clinical Pharmacology and Therapeutics","article-title":"Predictions of vancomycin exposure based on sparse data or demographics alone","author":"Yang","year":"2008"},{"key":"10.1016\/j.clinthera.2011.08.011_bib21","series-title":"Abstract presented at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Increased Mortality With Loss of Function of the Accessory Gene Regulator (agr) in Staphylococcus aureus Bacteremia","author":"Schweizer","year":"2008"},{"key":"10.1016\/j.clinthera.2011.08.011_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.011_bib23","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.08.011_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.08.011_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:38Z","timestamp":1758962918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811005492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0149291811005492"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.08.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and Costs Associated With a History of Vancomycin Exposure in Patients With MRSA-Related Complicated Bacteremia and Infective Endocarditis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}